

Håkan Hanberger

Peer-reviewed original articles

** original works in Lakartidningen

1. Hanberger, H., Nilsson, L.E., Kihlström, E. and Maller, R.: Postantibiotic effect of β -lactam antibiotics on *Escherichia coli* evaluated by bioluminescence assay of bacterial ATP. *Antimicrob. Agents Chemother.* 1990; 34:102-106. *
2. Hanberger, H., Nilsson, L.E., Maller, R. and Nilsson, M.: Pharmacodynamics of betalactam antibiotics on gram-negative bacteria: initial killing, morphology and post-antibiotic effect. *Scand. J. Infect. Dis. Suppl.*, 1991;74:118-123.
3. Isaksson, B., Hanberger, H., Maller, R., Nilsson, L.E. and Nilsson, M.: The post-antibiotic effect of amikacin alone and in combination with piperacillin on gram-negative bacteria. *Scand. J. Infect. Dis., Suppl.* 1991;74:129-132.
4. Isaksson, B., Hanberger, H., Maller, R. Nilsson L.E. and Nilsson, M.: Synergistic postantibiotic effect of amikacin and β -lactam antibiotics on *Enterococcus faecalis*. *J Antimicrob Chemother.* 1991;27 Suppl C:9-14
5. Hanberger, H., Nilsson, L.E., Maller, R. and Nilsson, M.: Evaluation of the postantibiotic effect of cefepime, cefotaxime and ceftazidime on gram-negative and gram-positive bacteria. *J. Chemother.*, 1991;3:Suppl.4:84-85.
6. Hanberger, H., Nilsson L.E., Nilsson, M. and Maller, R.: Postantibiotic effect of β -lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. *Eur.J. Clin. Microbiol. Infect. Dis.* 1991;10:927-934, *
7. Hanberger, H., Nilsson, L.E., Svensson, E. and Maller, R.: Synergic postantibiotic effect of mecillinam in combination with other β -lactam antibiotics in relation of morphology and initial killing. *Journal of Antimicrobial Chemotherapy*, , 1991;28:523-532. *
8. Isaksson, B., Hanberger, H., Maller, R. Nilsson, L. and Nilsson M.: Synergic post-antibiotic effect of amikacin in combination with β -lactam antibiotics on gram-negative bacteria. *J. Antimicrob. Chemother.*, , 1991;28:25-34. *
9. Hanberger, H., Nilsson, L.E., Maller, R. and Isaksson B.: Pharmacodynamics of daptomycin and vancomycin on *Enterococcus faecalis* and *Staphylococcus aureus* demonstrated by studies of initial killing and postantibiotic effect and influence of Ca^{2+} and albumin on these drugs. *Antimicrob. Chemother.* 1991;35:1710-1716. *
10. Hanberger H. Pharmacodynamic effects of antibiotics, Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. *Scandinavian Journal of Infectious Diseases* 1992; (Suppl 81):1-52.
11. Hanberger, H., Svensson, E., Nilsson, M., Nilsson, L.E., Hörnsten E. G. and Maller, M.: Effects of imipenem on *Escherichia coli* using bioluminescence, viable counting and microscopy. *J. Antimicrob. Chemother.* 1993;31:245-260.
12. Hanberger, H, Nilsson, L.E., Nilsson, M. and Maller, R.: Postantibiotic effect of β -lactam antibiotics, daptomycin and vancomycin on *Staphylococcus aureus*. *J. Chemother.* 1993;(5)S1:168-169.
13. Hanberger, H, Nilsson, L.E., Svensson, E. and Nilsson, M. : Pharmacodynamic effects of imipenem and meropenem on non-growing and growing gram-negative bacteria: initial killing and postantibiotic effect. *J Chemother.* 1993;(5),S1:119-120.
14. Hanberger, H. and Nilsson, L.E: Retain intermittent dosing of carbapenems. *Antimicrob. Agents Chemother.* 1994;38:159-160.
15. Hanberger, H., Svensson, E., Nilsson, L.E. and Nilsson, M. : Pharmacodynamic effects of meropenem on gram-negative bacteria. *Eur. J. Clin. Microbiol. Infect Dis.* , 1995;14:383-390.

16. Hanberger, H., Svensson, E., Nilsson, L.E. and Nilsson, M.: Control related effective regrowth time (CERT) and post antibiotic effect (PAE) of meropenem on gram-negative bacteria studied by bioluminescence and viable count. *J. Antimicrob. Chemother.* 1995;35:585-592.
17. Sörberg, M., Nilsson, M, Hanberger, H and Nilsson, L.E. Morphologic conversion of *Helicobacter pylori* from bacillary to coccoid form. *European Journal of Clinical Microbiology and Infectious Diseases* 1996; 15:216-219.
18. Hanberger, H och Nilsson, L. E.: Increased antibiotic resistance of intestinal bacteria. *Lakartidningen* 1996;93:148-154.
19. Svensson, E., Hanberger, H. and Nilsson, L.E.: Pharmacodynamic effects on growing and nongrowing *Staphylococcus epidermidis*. *Antimicrob. Agents Chemother.* 1997;41:107-111.
20. Svensson E, Hanberger H, Nilsson M and Nilsson LE. Factors affecting development of rifampicin resistance in biofilm-producing *Staphylococcus epidermidis*. *Journal Antimicrobial Chemotherapy*, 1997;39:817-820.
21. Hanberger H, Nilsson LE and the swedish study group. High frequency of antibiotic resistance among gram-negative isolates in intensive care units at ten Swedish hospitals. *Clinical Microbiology and Infection.* 1997; 3:208-215,
22. Sörberg M., Nilsson M., Hanberger, H. and Nilsson L.E., Pharmacodynamic effects of antibiotics and acid pump inhibitors on *Helicobacter pylori*. *Antimicrobial Agents and Chemotherapy* 1997;22: 2218-222..
23. Hanberger H, Hoffman M, Lindgren S and Nilsson LE. High incidence of antibiotic resistance among bacteria in intensive care units at a university hospital in Sweden. *Scandinavian Journal of Infectious Diseases* 1997; 29:607-614.
24. Hanberger H, Nilsson. L.E. A multicenter study shows alarming results. High antibiotic resistance within Swedish intensive care. *Lakartidningen*, 1997;94:2381-2386.
25. Sörberg M, Hanberger H, Nilsson M and Nilsson LE. Risk of development of resistance to amoxicillin, clarithromycin and metronidazole in *Helicobacter pylori*. *Antimicrobial Agents Chemother.* 1998;42;1222-12228.
26. Hanberger H, Garcia-Rodriguez J, Goossens H, Gobernado M, Nilsson LE, Struelens MJ and the European ICU-Study Group. Antibiotic Susceptibility Among Aerobic Gramnegative Bacilli in Intensive Care Units in 5 European countries. 1999;*JAMA*, 281:67-71.
27. Svensson E, , Hanberger H., Nilsson M, Nilsson LE. Pharmacodynamic Effects of amikacin, ciprofloxacin and imipenem on growing and nongrowing *Escherichia coli*. and *Pseudomonas aeruginosa*., *Clinical Microbiology and Infection* 1999;5:140-148.
28. Erlandsson C-M, Hanberger H and Eliasson I, Hoffmann M, Isaksson B, Lindgren S, Nilsson LE, Sörén L, Walther S in the ICU Study Group of South East of Sweden. Surveillance of Antibiotic Resistance in ICUs present in the southeast of Sweden. *Acta Anaesthesiologica Scandinavia.* 1999; 43: 815-820.
29. Hanberger H, Nilsson LE, Claesson B, Kjellberg E, Kärnell A, Larsson P, Rylander M, Svensson E, Sörberg M, Sörén L, Wretling B. New species-related MIC breakpoints for early detection of resistance development among gram-negative bacteria in intensive care units.*Journal of Antimicrobial Chemotherapy* 1999; 44: 611-619.
30. Hanberger H, Nilsson, LE. The intensive care unit is a hot zone for antibiotic resistance. *Lakartidningen.* 1999; 96:1277-1277-
31. Hanberger H, Diekema D , Fluit A, Jones R, Struelens M, Spencer R , Wolff M. Surveillance of antibiotic resistance in European ICUs. *J Hospital Infect*; 2001;48:161-176.
32. Hällgren A., Abednazari H, Ekdahl C, Hanberger H, Nilsson M., Samuelsson A, Svensson E, Nilsson LE and the Swedish ICU study group. Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoints systems. *J Antimicrob Chemother.* 2001; 48:53-62.

33. Hanberger H. Big differences when it comes to antibiotic resistance between European intensive care units. *Läkartidningen*. 2001;98:4827-8.
34. Saeedi B., Hällgren A., Jonasson J., Nilsson LE., Hanberger H., Isaksson B. Modified pulsed-field gel electrophoresis protocol for typing of enterococci. *APMIS*.2002;110:869-874.
35. Walther S, Erlandsson M, Burman LG, Cars O, Gill H, Hoffman M, Isaksson B, Kahlmeter G, Lindgren S, Nilsson LE, Olsson-Liljequist B, Hanberger H and the STRAMA-ICU study group. Antibiotic consumption, prescription practices and bacterial resistance in a cross section of Swedish intensive care units *Acta Anaesth Scand* 2002; 46:1075-1081.
36. Hällgren A., Saeedi B., Nilsson M., Monstein HJ., Isaksson B., Hanberger H., Nilsson LE. Genetic relatedness among *Enterococcus faecalis* with transposon mediated high-level gentamicin resistance in Swedish intensive care unites. *Journal of Antimicrobial Chemotherapy*. 2003;52:162-167.
37. Hanberger H., Erlandsson M., Burman L. G., Cars O, Gill H, Lindgren S, Nilsson L. E, Olsson-Liljequist B, Walther S. and the ICU-STRAMA Study Group. High Antibiotic Susceptibility Among Bacterial Pathogens In Swedish ICUs. Report from a nation-wide surveillance program using TA90 as anovel index of susceptibility. *Scand J Infect Dis* 2004;36:24-30.
38. Saeedi B., Hällgren A., Isaksson B., Jonasson J., Nilsson LE., Hanberger H. Genetic relatedness of *Enterococcus faecalis* isolates with high-level gentamicin resistance from patients with bacteraemia in the south east of Sweden 1994-2001. *Scand J Inf Dis*. 2004;36:405-409.
39. Hallgren A, Burman LG, Isaksson B, Olsson-Liljeqvist B, Nilsson LE, Saeedi B, Walther S, Hanberger H. Rectal colonization and frequency of enterococcal cross-transmission among prolonged-stay patients in two Swedish intensive care units. *Scand J Infect Dis*. 2005;37:561-571.
40. Saeedi B, Tarnberg M, Gill H, Hallgren A, Jonasson J, Nilsson LE, Isaksson B, Kuhn I, Hanberger H. Phene Plate (PhP) biochemical fingerprinting. A screening method for epidemiological typing of enterococcal isolates. *APMIS*. 2005;113:603-12.
41. Ekdahl C, Hanberger H, Hallgren A, Nilsson M, Svensson E, Nilsson LE. Rapid decrease of free vancomycin in dense staphylococcal cultures. *Eur J Clin Microbiol Infect Dis*. 2005;24:596-602.
42. Walther SM, Agvald-Ohman C, Blomqvist H, Monnet DL, Nilsson LE, Hanberger H. Multiresistant bacteria bigger and bigger threat in Swedish ICU. Quality assurance of hygiene routines and registration of complications are needed. *Lakartidningen*. 2006;103:3930-3.
43. Erlandsson M, Burman LG, Cars O, Gill H, Nilsson LE, Walther SM, **Hanberger H**. Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. *Scand J Infect Dis*. 2007;39:63-9.
44. Scicluna E.A, **Hanberger H**. Surveillance of Antimicrobial Resistance in Intensive Care Setting at St Luke's Hospital, Malta. *International Journal of Infection Control* 2007;3:1-7.
45. Claesson C, Hällgren A, **Hanberger H**, Nilsson M, Nilsson LE and the SCOPE study group. Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in four north European countries *Scand J Infect Dis*. 2007;39:1002-12
46. **Hanberger H**, Burman LG, Cars O, Erlandsson M, Gill H, Nilsson LE, Nordlinder D, Walther SM; ICU STRAMA Study Group. Low antibiotic resistance rates in *Staphylococcus aureus*, *Escherichia coli* and *Klebsiella* spp but not in *Enterobacter* spp and *Pseudomonas aeruginosa*: a prospective observational study in 14 Swedish ICUs over a 5-year period. *Acta Anaesthesiol Scand*. 2007;51:937-41.
47. Erlandsson M, Gill H, Nordlinder D, Giske CG, Jonas D, Nilsson LE, Walther S, **Hanberger H**. Antibiotic susceptibility patterns and clones of *Pseudomonas aeruginosa* in Swedish ICUs. *Scand J Infect Dis*. 2008;40:487-94.

48. Mölstad S, Erntell M, **Hanberger H**, Melander E, Norman C, Skoog G, Stålsby Lundborg CS, Söderström A, Torell E, Cars O. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. *Lancet Infect Dis.* 2008;8:125-32
49. Hällgren A, Claesson C, Saeedi B, Monstein HJ, **Hanberger H**, Nilsson LE. Molecular detection of aggregation substance, enterococcal surface protein, and cytolysin genes and in vitro adhesion to urinary catheters of *Enterococcus faecalis* and *E. faecium* of clinical origin. *Int J Med Microbiol.* 2009;299:323-32.
50. **Hanberger H**, Arman D, Gill H, Jindrák V, Kalenic S, Kurcz A, Licker M, Naaber P, Scicluna EA, Vanis V, Walther SM. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. *Intensive Care Med.* 2009;35:91-100.
51. ****Hanberger H**, Odenholt I, Giske CG, Kahlmeter G. Time to abandon "the house wine". Stop for uncritical empiric use of cefuroxime. *Klinik och Vetenskap. Lakartidningen.* 2009;106:291-2.
52. Walther S, Gill H, **Hanberger H**; Swedish Intensive Care Registry (SIR); Swedish strategic programme against antibiotic resistance in critical care (SIR-IVAStrama). Implementation of selective digestive decontamination in the intensive care unit: a word of caution. *Acta Anaesthesiol Scand.* 2010;54:526-7.
53. Hammarskjöld F, Berg S, **Hanberger H**, Malmvall BE. Low incidence of arterial catheter infections in a Swedish intensive care unit: risk factors for colonisation and infection. *J Hosp Infect.* 2010;76:130-4.
54. Ostholm-Balkhed A, Tärnberg M, Nilsson M, Johansson AV, **Hanberger H**, Monstein HJ, Nilsson LE. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden. *Scand J Infect Dis.* 2010;42:831-8.
55. Chabok A, Tärnberg M, Smedh K, Pålman L, Nilsson LE, Lindberg C, **Hanberger H**. Prevalence of fecal carriage of antibiotic-resistant bacteria in patients with acute surgical abdominal infections. *Scand J Gastroenterol.* 2010;45:1203-10.
56. Tärnberg M, Ostholm-Balkhed A, Monstein HJ, Hällgren A, **Hanberger H**, Nilsson LE. In vitro activity of beta-lactam antibiotics against CTX-M-producing *Escherichia coli*. *Eur J Clin Microbiol Infect Dis.* 2011;30:981-7.
57. Johansson M, Phuong DM, Walther SM, **Hanberger H**. Need for improved antimicrobial and infection control stewardship in Vietnamese intensive care units. *Trop Med Int Health.* 2011;16:737-43.
58. **Hanberger H**, Walther S, Leone M, Barie PS, Rello J, Lipman J, Marshall JC, Anzueto A, Sakr Y, Pickkers P, Felleiter P, Engoren M, Vincent JL; EPIC II Group of Investigators. Increased mortality associated with methicillin-resistant *Staphylococcus aureus* (MRSA) infection in the Intensive Care Unit: results from the EPIC II study. *Int J Antimicrob Agents.* 2011;38:331-5.
59. **Hanberger H**, Giske C. G., Giamarellou, H. "When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock." *Current infectious disease reports* 2011;13: 416-425.
60. Samuelsson A, Isaksson B, Chabok A, Jonasson J, Nilsson LE, Eriksson O, **Hanberger H**. Changes in the aerobic faecal flora of patients treated with antibiotics for acute intra-abdominal infection. *Scand J Infect Dis.* 2012;44:820-7.
61. Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, **Hanberger H**, Herwaldt LA, van Keulen PH, Kluytmans JA, Kola A, Kuchenbecker RS, Lingaas E, Meessen N, Morris-Downes MM, Pottinger JM, Rohner P, dos Santos RP, Seifert H, Wisplinghoff H, Ziesing S, Walker AS, Bonten MJ. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. *Clin Infect Dis.* 2013;56:798-805.
62. Östholm Balkhed Å, Tärnberg M, Monstein HJ, Hällgren A, **Hanberger H**, Nilsson LE. High frequency of co-resistance in CTX-M-producing *Escherichia coli* to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomicin, in a county of Sweden. *Scand J Infect Dis.* 2013;45:271-8.

63. Ostholm-Balkhed A, Tärnberg M, Nilsson M, Nilsson LE, **Hanberger H**, Hällgren A; on behalf of the Travel Study Group of Southeast Sweden. Travel-associated faecal colonization with ESBL-producing Enterobacteriaceae: incidence and risk factors. *J Antimicrob Chemother.* 2013 Sep;68:2144-53
64. Taxbro K, Berg S, Hammarskjöld F, **Hanberger H**, Malmvall BE. A prospective observational study on 249 subcutaneous central vein access ports in a Swedish county hospital. *Acta Oncol.* 2013;52:893-901.
65. **Hanberger H**, Edlund C, Furebring M, G Giske C, Melhus A, Nilsson LE, Petersson J, Sjölin J, Ternhag A, Werner M, Eliasson E; Swedish Reference Group for Antibiotics. Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). *Scand J Infect Dis.* 2013;45:161-75.
66. Wertheim HF, Chandna A, Vu PD, Pham CV, Nguyen PD, Lam YM, Nguyen CV, Larsson M, Rydell U, Nilsson LE, Farrar J, Nguyen KV, **Hanberger H**. Providing impetus, tools, and guidance to strengthen national capacity for antimicrobial stewardship in Vietnam. *PLoS Med.* 2013;10(5):e1001429. doi: 10.1371/journal.pmed.1001429. Epub 2013 May 7.
67. Hammarskjöld F, Mernelius S, Andersson R, Berg S, **Hanberger H**, Löfgren S, Malmvall BE, Petzold M, Matussek A. Possible transmission of *Candida albicans* on an intensive care unit: genotype and temporal cluster analyses. *J Hosp Infect.* 2013;85:60-5
68. Samuelsson A, Isaksson B, **Hanberger H**, Olhager E. Late-onset neonatal sepsis, risk factors and interventions: an analysis of recurrent outbreaks of *Serratia marcescens*, 2006-2011. *J Hosp Infect.* 2014 Jan;86(1):57-63. doi: 10.1016/j.jhin.2013.09.017. Epub 2013 Oct 23
69. **Lundin F, Personne M, **Hanberger H**. Botulism - behandlingsbar sällsynt förgiftning. *Lakartidningen.* 2014 Mar 19-Apr 1;111(12-13):551-2.
70. **Ternhag A, Giske C, **Hanberger H**. Aminoglykosider är effektiva, men oto- och njurtoxiska. Kunskapsunderlag från RAF och SILF om nytta-risk med aminoglykosider. *Lakartidningen.* 2014 Feb 12-18;111(7):268-9.
71. Hammarskjöld F, Berg S, **Hanberger H**, Taxbro K, Malmvall BE. Sustained low incidence of central venous catheter-related infections over six years in a Swedish hospital with an active central venous catheter team. *Am J Infect Control.* 2014 Feb;42(2):122-8. doi: 10.1016/j.ajic.2013.09.023
72. **Hanberger H**, Gunilla Skoog, Anders Ternhag, Giske C. Antibiotic Stewardship in Swedish hospitals. *Ups J Med Sci.* 2014 May;119(2):154-61. doi: 10.3109/03009734.2014.909911. Epub 2014 Apr 11.
73. **Hanberger H**, Antonelli M, Holmbom M, Lipman J, Pickkers P, Leone M, Rello J, Sakr Y, Walther SM, Vanhems P, Vincent JL for the EPIC II Group Investigators. Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. *BMC Infect Dis.* 2014 Sep 22;14:513. doi: 10.1186/1471-2334-14-513.
74. Petropoulos EA, **Hanberger H**, Giske CG. *Lakartidningen* [New antibiotics with activity against multidrug-resistant enterobacteriaceae. Combination preparations are now being tested clinically]. [Article in Swedish] *Lakartidningen.* 2014 Jun 11-17;111(24):1050-1.
75. **Åkerlund A, Sundqvist M, **Hanberger H**, Åhrén C, Serrander L, Giske C. Response times can be shortened in microbiological diagnosis of sepsis. Better opening hours in laboratories and active advice enables faster therapy. [Article in Swedish]. *Lakartidningen.* 2015 Feb 10;112. pii: C73S
76. Leander G, Eliasson E, **Hanberger H**, Giske C. Betalaktamantibiotika och frågan om dosregim vid svår infektion – Förlängd infusion teoretiskt tilltalande - ännu saknas evidens för klinisk nytta. *Lakartidningen.* 2015 Mar 24;112.
77. Phu VD, Wertheim HF, Larsson M, Nadjm B, Dinh QD, Nilsson LE, Rydell U, Le TT, Trinh SH, Pham HM, Tran CT, Doan HT, Tran NT, Le ND, Huynh NV, Tran TP, Tran BD, Nguyen ST, Pham TT, Dang TQ, Nguyen CV, Lam YM, Thwaites G, Van Nguyen K, **Hanberger H**. Burden of Hospital Acquired Infections and Antimicrobial Use in Vietnamese Adult Intensive Care Units. *PLoS One.* 2016 Jan 29;11(1):e0147544. doi:10.1371/journal.pone.0147544. eCollection 2016. PubMed PMID: 26824228;

78. Fransén J, Huss FR, Nilsson LE, Rydell U, Sjöberg F, **Hanberger H**. Surveillance of antibiotic susceptibility in a Swedish Burn Center 1994-2012. *Burns*. 2016 Sep;42(6):1295-303. doi: 10.1016/j.burns.2016.01.025. Epub 2016 May 27. PubMed PMID: 27241732.
79. Skoog G, Struwe J, Cars O, **Hanberger H**, Odenholt I, Prag M, Skärlund K, Ulleryd P, Erntell M. Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: data for actions 2003-2010. *EuroSurveill*. 2016 Jun 23;21(25). doi: 10.2807/1560-7917.ES.2016.21.25.30264.
80. Holmbom M, Giske CG, Fredrikson M, Östholm Balkhed Å, Claesson C, Nilsson LE, Hoffmann M, **Hanberger H**. 14-Year Survey in a Swedish County Reveals a Pronounced Increase in Bloodstream Infections (BSI). Comorbidity - An Independent Risk Factor for Both BSI and Mortality. *PLoS One*. 2016 Nov 11;11(11):e0166527. doi:10.1371/journal.pone.0166527. eCollection 2016. PubMed PMID: 27835663; PubMed Central PMCID: PMC5106013.
81. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, **Hanberger H**, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, Paiva JA, Read RC, Rigau D, Timsit JF, Welte T, Wunderink R. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). *Eur Respir J*. 2017 Sep 10;50(3). pii: 1700582. doi: 10.1183/13993003.00582-2017. Print 2017 Sep. PubMed PMID: 28890434.
82. Mölstad S, Löfmark S, Carlin K, Erntell M, Aspevall O, Blad L, **Hanberger H**, Hedin K, Hellman J, Norman C, Skoog G, Stålsby-Lundborg C, Tegmark Wisell K, Åhrén C, Cars O. Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance. *Bull World Health Organ*. 2017 Nov 1;95(11):764-773. doi: 10.2471/BLT.16.184374. Epub 2017 Oct 3. PubMed PMID: 29147057; PubMed Central PMCID: PMC5677604.
83. **Hanberger H**, Claesson K. [nya rekommendationer vid sjukhusförvärd pneumoni]. *Lakartidningen*. 2016 Feb 26;113.pii: DW77. Swedish. PubMed PMID: 26928691.
84. Le NK, Hf W, Vu PD, Khu DT, Le HT, Hoang BT, Vo VT, Lam YM, Vu DT, Nguyen TH, Thai TQ, Nilsson LE, Rydell U, Nguyen KV, Nadjm B, Clarkson L, **Hanberger H**, Larsson M. High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: A multi-centre point prevalence survey. *Medicine (Baltimore)*. 2016 Jul;95(27):e4099. doi: 10.1097/MD.0000000000004099. PubMed PMID: 27399106.
85. Dettenkofer M, Humphreys H, Saenz H, Carlet J, **Hanberger H**, Ruef C, Widmer A, Wolkewitz M, Cookson B. Key priorities in the prevention and control of healthcare-associated infection: a survey of European and other international infection prevention experts. *Infection*. 2016 Dec;44(6):719-724. Epub 2016 May 25. PubMed PMID: 27225779.
86. Berglund B, Claesson C, Nilsson LE, **Hanberger H**. High Prevalence of Heterogeneously Glycopeptide-Intermediate Coagulase-Negative Staphylococci in Sternal Wounds. *Antimicrob Agents Chemother*. 2016 Jul 22;60(8):5097-8. Doi:10.1128/AAC.00217-16. Print 2016 Aug. PubMed PMID: 27216070.
87. Berglund B, Hoang NTB, Tärnberg M, Le NK, Svartström O, Khu DTK, Nilsson M, Le HT, Welander J, Olson L, Larsson M, Nilsson LE, **Hanberger H**. Insertion sequence transpositions and point mutations in mgrB causing colistin resistance in a clinical strain of carbapenem-resistant klebsiella pneumoniae from vietnam. *Int J Antimicrob Agents*. 2017 Nov 24. pii: S0924-8579(17)30429-6. doi: 10.1016/j.ijantimicag.2017.11.012. [Epub ahead of print] PubMed PMID: 29180281.
88. Berglund B, Hoang NTB, Tärnberg M, Le NK, Welander J, Nilsson M, Khu DTK, Nilsson LE, Olson L, Le HT, Larsson M, **Hanberger H**. Colistin- and carbapenem-resistant Klebsiella pneumoniae carrying mcr-1 and blaOXA-48 isolated at a paediatric hospital in Vietnam. *J Antimicrob Chemother*. 2018 Apr 1;73(4):1100-1102. doi: 10.1093/jac/dkx491. PubMed PMID: 29253209.
89. Phu VD, Nadjm B, Duy NHA, Co DX, Mai NTH, Trinh DT, Campbell J, Khiem DP, Quang TN, Loan HT, Binh HS, Dinh QD, Thuy DB, Lan HNP, Ha NH, Bonell A, Larsson M, Hoan HM, Tuan ĐQ, **Hanberger H**, Minh HNV, Yen LM, Van Hao N, Binh NG, Chau NVV, Van Kinh N, Thwaites GE, Wertheim HF, van Doorn HR, Thwaites CL. Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology. *J Intensive Care*. 2017 Dec 19;5:69. doi:10.1186/s40560-017-0266-4. eCollection 2017. PubMed PMID: 29276607; PubMed Central PMCID: PMC5738227.

90. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, **Hanberger H**, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, Paiva JA, Read RC, Rigau D, François Timsit J, Welte T, Wunderink R. Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. *ERJ Open Res.* 2018 Jun 26;4(2). pii: 00028-2018. doi:10.1183/23120541.00028-2018. eCollection 2018 Apr.
91. Östholm Balkhed Å, Tärnberg M, Nilsson M, Nilsson LE, **Hanberger H**, Hällgren A; Southeast Sweden Travel Study Group. Duration of travel-associated faecal colonisation with ESBL-producing Enterobacteriaceae - A one year follow-up study. *PLoS One.* 2018 Oct 24;13(10):e0205504. doi: 10.1371/journal.pone.0205504 eCollection 2018.
92. **Giske C, **Hanberger H**, Kahlmeter G. [A new SIR definition for antimicrobial susceptibility testing]. *Lakartidningen.* 2019 Jan 31;116. pii: FHCX. [Article in Swedish].
93. Andersson M, Östholm-Balkhed Å, Fredrikson M, Holmbom M, Hällgren A, Berg S, **Hanberger H**. Delay of appropriate antibiotic treatment is associated with high mortality in patients with community-onset sepsis in a Swedish setting. *Eur J Clin Microbiol Infect Dis.* 2019 Mar 25. doi: 10.1007/s10096-019-03529-8.
94. Taxbro K, Hammarskjöld F, Thelin B, Lewin F, Hagman H, **Hanberger H**, Berg S. Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial. *Br J Anaesth.* 2019 Jun;122(6):734-741. doi: 10.1016/j.bja.2019.01.038. Epub 2019 Apr 17.
95. Peters L, Olson L, Khu DTK, Linnros S, Le NK, **Hanberger H**, Hoang NTB, Tran DM, Larsson M. Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam. *PLoS One.* 2019 May 8;14(5):e0215666. doi: 10.1371/journal.pone.0215666. eCollection 2019.
96. Dien M. Tran, Mattias Larsson, Linus Olson, Ngoc T.B. Hoang, Ngai K. Le, Dung T.K. Khu, Hung D. Nguyen, Tam V. Vu, Tinh H. Trinh, Thinh Q. Le, Phuong T.T. Phan, Binh G. Nguyen, Nhung H. Pham, Bang H. Mai, Tuan V. Nguyen, Phuong T.K. Nguyen, Nhan D. Le, Tuan M. Huynh, Le T.H. Thu, Tran Chi Thanh, Björn Berglund, Lennart E. Nilsson, Elin Bornefall, Le H. Song, **Håkan Hanberger**. *J Infect.* 2019 May 21. pii: S0163-4453(19)30157-4. Doi10.1016/j.jinf.2019.05.013.
97. Dellgren L, Claesson C, Högdahl M, Forsberg J, **Hanberger H**, Nilsson LE, Hällgren A. Phenotypic screening for quinolone resistance in *Escherichia coli*. *European Journal of Clinical Microbiology & Infectious Diseases* (accepted June 2019)

Books and varia

1. **Hanberger H**, Odenholt I. Antibiotikaval II Internetmedicin; 1:1–28, 2007
2. Marcus Erlandsson, **Håkan Hanberger**, Multiresistenta bakterier – ett relativt litet problem på svenska IVA. *Smittskydd* 2007; (5): 40.
3. **Hanberger H**, Dannetun E, Rutberg H. New Strama-work in Ostergotland. The LIRA-concept gives best results. *Lakartidningen.* 2007;104:3351-2.
4. **Hanberger H**, Persson AC, Bergdahl B. (2008) Web-scenarios –building on reality and supporting the problem-based learning structure at an undergraduate medical programme. In Cameron, L. & Dalziel, J. (Eds), *Proceedings of the 2008 European LAMS Conference: Practical Benefits of Learning Design.* June 25th-27th, 2008. Cadiz, Spain: LAMS Foundation. ISBN: 978-1-74138-286-0.
5. **Hanberger, H.** (Ed), *Sepsishäftet, handläggning av sepsis på akuten och IVA.* 2008, ISBN 978-91-7000-150-5.
6. André M, Blad L, Dohnhammar U, Erntell M, **Hanberger H**, Isaksson B, Melander E, Mölstad S, Norman C, Lundborg CS, Ulleryd P, Wahlberg K; Strama; Strategigruppen för rationell antibiotika-användning och minskad antibiotikaresistens. Strama suggests a national goal: Halved antibiotics prescriptions in metropolitan areas in five years. *Lakartidningen.* 2009;106:3133-4.
7. Agvald-Ohman C, **Hanberger H**, Struwe J, Walther SM. The "push" and "pull" method to reduce nosocomial infections at ICU. A pilot project with an active follow up. *Lakartidningen.* 2010;107:28-31.

8. Pulcini C, Bush K, Craig WA, Fridodt-Møller N, Grayson ML, Mouton JW, Turnidge J, Harbarth S, Gyssens IC; ESCMID Study Group for Antibiotic Policies (**Collaborators:** Hysa A, Pipero P, Turnidge J, Theuretzbacher U, Gyssens I, Kantardjiev T, Lowe D, Vlahovic-Palcevski V, Fridodt-Møller N, Laius O, Lutsar I, Bergman M, Pulcini C, Matz S, Ziegelmann A, Giamarellou H, Benkö R, Nagy E, Arnórsson M, Bergin C, O'Connor M, Tacconelli E, Raka L, Dumpis U, Jurkevičienė A, Bruch M, Heisbourg E, Bosevska G, Zarb P, Gyssens I, Simonsen GS, Hryniewicz W, Ramos Dias LC, Lupse M, Carevic B, Beović B, Paño Pardo JR, **Hanberger H**, Harbarth S, Akova M, Kennedy H, Marwick C, Craig W.. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. *Clin Infect Dis*. 2012;54:268-74
9. **Hanberger H**, Fredriksson M, Ternhag A, Giske CG. Rational use of aminoglycosides - author response. *Scand J Infect Dis*. 2013;45:655-6.
10. **Hanberger H** (Ed) Sepsis på akuten och IVA, diagnostik och antibiotikaterapi. 2017, ISBN:978-91-7685-614-7